APA (7th ed.) Citation

JM, V., S, G., PJ, B., RG, B., M, L., L, L., . . . JO, A. (2023). Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study. British journal of haematology, 202(1), 116. https://doi.org/10.1111/bjh.18821

Chicago Style (17th ed.) Citation

JM, Vose, Ganguly S, Bierman PJ, Bociek RG, Lunning M, Lyden L, Meza JL, Caimi PF, and Armitage JO. "Lenalidomide Maintenance Following High-dose Therapy and Autologous Haematopoietic Stem Cell Transplantation in Chemo-resistant or High-risk Non-Hodgkin Lymphoma: A Phase I/II Study." British Journal of Haematology 202, no. 1 (2023): 116. https://doi.org/10.1111/bjh.18821.

MLA (9th ed.) Citation

JM, Vose, et al. "Lenalidomide Maintenance Following High-dose Therapy and Autologous Haematopoietic Stem Cell Transplantation in Chemo-resistant or High-risk Non-Hodgkin Lymphoma: A Phase I/II Study." British Journal of Haematology, vol. 202, no. 1, 2023, p. 116, https://doi.org/10.1111/bjh.18821.